Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653011 | 0.96 | GCK (0.77) | GCK | |
| SCHEMBL2651891 | 0.87 | GCK (1.00) | GCK | |
| SCHEMBL2652248 | 0.87 | GCK (0.81) | GCK | |
| SCHEMBL4758886 | 0.87 | GCK (1.00) | GCK | |
| SCHEMBL14032123 | 0.86 | GCK (0.77) | GCK | |
| SCHEMBL2650772 | 0.86 | GCK (0.77) | GCK | |
| SCHEMBL2511295 | 0.86 | GCK (0.80) | GCK | |
| SCHEMBL2511299 | 0.86 | GCK (0.80) | GCK | |
| SCHEMBL2651487 | 0.84 | GCK (1.00) | GCK | |
| SCHEMBL2652104 | 0.84 | GCK (1.00) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | PROSIDION LIMITED (GB) | 2008-10-02 | — | — | US | claimed |
| EP-1740560-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | Prosidion Limited (GB) | 2007-01-10 | — | — | EP | claimed |
| WO-2005103021-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | PROSIDION LIMITED (GB) | 2005-11-03 | — | — | WO | claimed |
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | PROSIDION LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | PROSIDION LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | PROSIDION LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| EP-1740560-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | Prosidion Limited (GB) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005103021-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | PROSIDION LIMITED (GB) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | IAPP, GPR119, CPT1A | GCK 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.